As people with CF become more physiologically similar to the general population with the advent of CFTR modulator therapies, the impact of overweight and obesity on CF outcomes such as on pulmonary function, body composition, and their consequences for cardio-metabolic health warrants further investigation [62]. This evidence concerns the gene CFTR and obesity disorder.